UNSPSC 51262502: Guanazodine

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C9H20N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N05KQ38YI, chemically known as guanidine, ((octahydro-2-azocinyl)methyl)- (8ci,9ci) but generally known as guanazodine, which bears US NIH Compound Identifier 36054. European Medicines Agency schedules Guanazodine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07981MIG. The term GUANAZODINE is an International Non-Proprietary Name.

UNSPSC 51262502 Guanazodine, a Commodity code, shows minimal relevant recent activity in state and local procurement. The code nominally describes a specific pharmaceutical compound, but the recent opportunities tagged to it involve naloxone procurement and direct-to-manufacturer pharmacy benefit programs — neither of which aligns with guanazodine as a pharmaceutical input or end product. State and local health agencies, counties, and state health commissions do solicit pharmaceutical and medical-supply purchases, but the mismatch between the code's stated scope and the work actually appearing under it suggests that this particular Commodity code is either misapplied in current posting workflows or sees limited genuine demand in the state and local market.

The two opportunities on record originate from different issuing bodies and procurement phases. Seminole County, Florida issued IFB 60459723LAS in late June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (a date inconsistency suggests data quality issues in the source); the procurement specifies quarterly deliveries, E-Verify compliance, drug-free workplace certification, and potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs rather than to solicit specific products. The code shows no concentration among repeat buyers, no standout geographic focus beyond these two Florida and Texas instances, and no evidence of ongoing activity that would justify focused business development effort at this time.